StockWatch
·

Ami Organics Ltd

BSE: 543349

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
441.09
+34.9%+40.4%
Expenditure
260.01
+16.7%+19.9%
Net Profit
135.74
+78.8%+86.2%
OPM %
42.34%
+8.32pp+10.69pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.00123.51247.01370.52494.03Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Acutaas Chemicals' Q2 FY27 consolidated PAT jumps 71% YoY as margins expand to ~40%

specialty chemicals · pharma intermediates · margin expansion

ResultsQ2 FY2727 Oct 20263 minPharma & Healthcare

Acutaas Chemicals eyes margin durability amid CDMO expansion push

CDMO growth · margins · semiconductor expansion

Result previewQ2 FY2724 Oct 20263 minPharma & Healthcare

Acutaas Opens Its Korea Chemicals Plant and Adds ₹212 Cr Gujarat Capex; ECMS Incentive Covers Battery Additives

Acutaas · Indichem · semiconductor chemicals

Research28 Aug 20264 min
Latest
Quarterly Result27 Oct, 12:47 pm

Acutaas Chemicals' Q2 FY27 consolidated PAT jumps 71% YoY as margins expand to ~40%

Acutaas Chemicals (formerly Ami Organics) reported consolidated revenue of ₹436.92 Cr for Q2 FY27, up 42.7% year-on-year from ₹306.20 Cr and 32.5% sequentially from ₹329.67 Cr. Consolidated profit for the period (before minority interest) rose 71.4% YoY to ₹123.14 Cr from ₹71.86 Cr, with profit attributable to owners at ₹125.17 Cr (basic EPS ₹15.29 vs ₹8.82 a year ago) — profit growing well ahead of revenue YoY, the primary read on the quarter. No exceptional items appear in either the current or comparison periods, so this is a like-for-like beat, not a one-off. The profit growth was driven by margin expansion rather than any one-time item: operating margin (EBITDA/revenue) expanded to roughly 40.3% from 31.1% a year ago and 34.3% last quarter, while net margin rose to 28.2% from 22.7% YoY. The expansion sits mainly on the cost-of-materials and other-expense lines relative to revenue, consistent with a richer product mix and operating leverage as volumes scale, rather than pricing or forex tailwinds. Standalone and consolidated diverge materially on growth: standalone PAT of ₹135.74 Cr (EPS ₹16.58) grew 86.2% YoY, well ahead of the consolidated 71.4%, because consolidated numbers absorb drag from newer subsidiaries — notably Indichem Inc.'s South Korea semiconductor-materials plant (75%-owned via Acutaas Advance Material, ~₹200 Cr invested), inaugurated August 28, 2026 but still under trial runs at quarter-end. Against management's FY27 guidance of 25% revenue growth and stable margins versus FY26, H1 FY27 consolidated revenue of ₹766.59 Cr (+49.3% YoY) and the margin expansion both run well ahead — a clear beat on guidance. It also clears our pre-result preview, which had pencilled in revenue of ₹320-350 Cr, EBITDA margin of 33-35% and PAT of ₹100-120 Cr; the actual print topped every range. Management's press release frames the quarter as led by 'continued momentum in our Pharmaceutical Intermediates business, offset by softer performance in the Specialty Chemicals segment' — consistent with the revenue and margin mix seen here. The other corporate action this quarter, the October 17 acquisition of step-down subsidiary Enchem Ami Organics, is an intra-group restructuring completed after quarter-end with no impact on these numbers; it becomes a Q3 FY27 item to track alongside the Indichem ramp.

27 Oct 2026, 12:47 pm

Corporate Events

Board MeetingACUTAAS
2026
27Oct

Board Meeting

The meeting of the Board of Directors is scheduled to consid…

BSE Filing ↗
Board MeetingACUTAAS
2026
24Sep

Board Meeting

The 19th Annual General Meeting of the company is scheduled …

BSE Filing ↗
DividendACUTAAS
2026
17Sep

₹2.5 / share

BSE Filing ↗
Board MeetingACUTAAS
2026
22Aug

Board Meeting

The Board of Directors considered and approved the notice co…

BSE Filing ↗
Board MeetingACUTAAS
2026
24Jul

Board Meeting

The Board of Directors meeting is scheduled to consider and …

BSE Filing ↗
Board MeetingACUTAAS
2026
2Jul

Board Meeting

The Nomination and Remuneration Committee met today. The co…

BSE Filing ↗
Board MeetingACUTAAS
2026
30Apr

Board Meeting

The Board of Directors met on April 30, 2026. They recommen…

BSE Filing ↗
Board MeetingACUTAAS
2026
28Jan

Board Meeting

consider and approve Unaudited Standalone & Consolidated Fin…

BSE Filing ↗
Board MeetingACUTAAS
2025
17Oct

Board Meeting

consider and approve Unaudited Standalone & Consolidated Fin…

BSE Filing ↗
DividendACUTAAS
2025
18Sep

₹1.5 / share

BSE Filing ↗
Board MeetingACUTAAS
2025
30Jul

Board Meeting

consider and approve Unaudited Financial Results

BSE Filing ↗
Stock SplitACUTAAS
2025
25Apr

2

BSE Filing ↗
Stock SplitACUTAAS
2025
21Feb

1:2

BSE Filing ↗
Board MeetingACUTAAS
2025
28Jan

Board Meeting

Consider and approve Unaudited Standalone and Consolidated F…

BSE Filing ↗
Board MeetingACUTAAS
2024
29Oct

Board Meeting

consider and approve Unaudited Standalone & Consolidated Fin…

BSE Filing ↗
DividendACUTAAS
2024
13Sep

₹3 / share

BSE Filing ↗
Board MeetingACUTAAS
2024
26Apr

Board Meeting

Consider, evaluate and approve a proposal to raise funds by …

BSE Filing ↗
Board MeetingACUTAAS
2024
12Apr

Board Meeting

Consider and approve raising of funds

BSE Filing ↗
Board MeetingACUTAAS
2024
12Feb

Board Meeting

Consider and approve the Unaudited Standalone and Consolidat…

BSE Filing ↗
Board MeetingACUTAAS
2023
8Nov

Board Meeting

Consider and approve Unaudited Standalone and Consolidated F…

BSE Filing ↗
DividendACUTAAS
2023
18Sep

₹3 / share

BSE Filing ↗
Board MeetingACUTAAS
2023
4Aug

Board Meeting

consider and approve the proposal for issue of equity shares…

BSE Filing ↗